| Company |
Product |
Class/Structure |
MOA |
Lead indication |
Lead status |
| Basilea Pharmaceutica AG (SIX:BSLN) |
Ceftobiprole |
Beta-lactam |
Inhibit cell wall synthesis |
Hospital-acquired bacterial pneumonia (HABP) |
Under review (EU) |
| Johnson & Johnson (NYSE:JNJ)/Global Alliance for TB Drug Development |
Bedaquiline (TMC207) |
Diarylquinoline |
Inhibit mycobacterial ATP synthase |
Multi-drug resistant tuberculosis (TB) |
Under review (U.S./EU) |
| Otsuka Pharmaceutical Co. Ltd. |
Delamanid (OPC-67683) |
Nitroimidazole |
Inhibit mycolic-acid biosynthesis |
Multi-drug resistant TB |
Under review (EU); Ph III (U.S./Japan) |
| Advanced Life Sciences Holdings Inc. (Pink:ADLS) (A) |
Restanza cethromycin |
Ketolide |
Inhibit protein synthesis |
Community-acquired bacterial pneumonia (CABP) |
Ph III (obtained SPA in 2010) |
| AstraZeneca plc (LSE:AZN)/Forest Laboratories Inc. (NYSE:FRX) |
Avibactam / ceftazidime (CAZ104) |
Beta-lactamase inhibitor (avibactam); beta-lactam (ceftazidime) |
Inhibit beta lactamase; inhibit cell wall synthesis |
Complicated urinary tract infection (cUTI) |
Ph III |
| Cubist Pharmaceuticals Inc. (NASDAQ:CBST) |
Tazobactam /ceftolozane (CXA-201) |
Beta-lactamase inhibitor (tazobactam); beta-lactam (ceftolozane) |
Inhibit beta lactamase; inhibit cell wall synthesis |
cUTI; complicated intra-abdominal infection (cIAI) |
Ph III |
| Cubist Pharmaceuticals Inc. (NASDAQ:CBST) |
CB-315 |
Lipopeptide |
Membrane depolarization |
Clostridium difficile-associated diarrhea (CDAD) |
Ph III |
| Dong Wha Pharmaceutical Industrial Co. Ltd. (KSE:000020)/Iaso Pharma Inc. |
Zabofloxacin (PB-101) |
Fluoroquinolone |
Inhibit DNA replication |
Acute bacterial exacerbation of chronic obstructive pulmonary disease (COPD) |
Ph III |
| Dong-A Pharmaceutical Co. Ltd. (KSE:000640)/Trius Therapeutics Inc. (NASDAQ:TSRX)/Bayer AG (Xetra:BAYN) |
Tedizolid (TR-701) |
Oxazolidinone |
Inhibit protein synthesis |
Acute bacterial skin and skin structure infection (ABSSSI) |
Ph III |
| Durata Therapeutics Inc. (NASDAQ:DRTX) |
Dalbavancin |
Glycopeptide |
Inhibit cell wall synthesis |
ABSSSI |
Ph III |
| TaiGen Biotechnology Co. Ltd./Warner Chilcott plc (NASDAQ:WCRX) |
Nemonoxacin (TG-873870) |
Quinolone |
Inhibit DNA replication |
CABP |
Ph III |
| The Medicines Co. (NASDAQ:MDCO) |
Oritavancin |
Glycopeptide |
Inhibit cell wall synthesis |
ABSSSI |
Ph III (FDA complete response letter in 2008) |
| Toyama Chemical Co. Ltd./Astellas Pharma Inc. (Tokyo:4503) |
Garenoxacin (T-3811) |
Fluoroquinolone |
Inhibit DNA replication |
Bacterial infection |
Ph III; approved in Japan |
| Cempra Inc. (NASDAQ:CEMP)/Optimer Pharmaceuticals Inc. (NASDAQ:OPTR) |
Solithromycin (CEM-101) |
Ketolide |
Inhibit protein synthesis |
CABP |
Start Ph III 4Q12 |
| Paratek Pharmaceuticals Inc. |
Omadacycline (PTK796) |
Tetracycline |
Inhibit protein synthesis |
ABSSSI |
Start Ph III 1Q13 |
| Actelion Ltd. (SIX:ATLN) |
Cadazolid (179811) |
Oxazolidinone-quinolone hybrid |
Inhibit DNA replication and protein synthesis |
C. difficile infection |
Ph II |
| ActivBiotics Pharma LLC |
Rifalazil |
Rifamycin |
Inhibit RNA synthesis |
Chlamydia infection |
Ph II |
| Affinium Pharmaceuticals Ltd. |
AFN-1252 |
FabI enoyl-(acyl carrier protein) reductase inhibitor |
Inhibit fabI |
ABSSSI |
Ph II |
| CrystalGenomics Inc. (KOSDAQ:83790) |
CG400549 |
FabI enoyl-(acyl carrier protein) reductase inhibitor |
Inhibit fabI |
Complicated ABSSSI |
Ph II |
| GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) |
GSK1322322 |
Peptide deformylase (PDF) inhibitor |
Inhibit PDF |
Bacterial infection |
Ph II |
| Global Alliance for TB Drug Development/Novartis AG (NYSE:NVS; SIX:NOVN) |
PA-824 |
Nitroimidazole |
Inhibit cell wall and protein synthesis |
Multi-drug resistant TB |
Ph II |
| MerLion Pharmaceuticals Pte. Ltd./Novartis AG (NYSE:NVS; SIX:NOVN) |
Finafloxacin |
Fluoroquinolone |
Inhibit DNA replication |
Helicobacter pylori infection; Uncomplicated UTI (uUTI) |
Ph II |
| Achaogen Inc./Isis Pharmaceuticals Inc. (NASDAQ:ISIS) |
Plazomicin (ACHN-490) |
Aminoglycoside |
Inhibit protein synthesis |
cUTI |
Ph II |
| Furiex Pharmaceuticals Inc. (NASDAQ:FURX)/Johnson & Johnson (NYSE:JNJ) |
JNJ-32729463 ( JNJ-Q2) |
Fluoroquinolone |
Inhibit DNA replication |
ABSSSI; CABP |
Ph II |
| Nabriva Therapeutics AG/Forest Laboratories Inc. (NYSE:FRX) |
BC-3781 |
Pleuromutilin |
Inhibit protein synthesis |
ABSSSI |
Ph II |
| Novartis AG (NYSE:NVS) |
LFF571 |
Thiopeptide |
Inhibit protein synthesis |
C. difficile infection |
Ph II |
| Pfizer Inc. (NYSE:PFE) |
PNU-100480 |
Oxazolidinone |
Inhibit protein synthesis |
TB |
Ph II |
| PolyMedix Inc. (OTCBB:PYMX) |
Brilacidin (PMX-30063) |
Defensin-mimetics |
Membrane lysis |
ABSSSI |
Ph II |
| Rib-X Pharmaceuticals Inc. |
Delafloxacin (RX-3341) |
Fluoroquinolone |
Inhibit DNA replication |
ABSSSI |
Ph II |
| Rib-X Pharmaceuticals Inc. |
Radezolid (RX-1741) |
Oxazolidinone |
Inhibit protein synthesis |
CABP; uncomplicated skin and skin structure infection (uSSSI) |
Ph II |
| Sequella Inc. |
SQ109 |
Ethylene diamine |
Inhibit cell wall synthesis |
H. pylori infection; TB |
Ph II |
| Tetraphase Pharmaceuticals Inc. |
Eravacycline (TP-434) |
Tetracycline |
Inhibit protein synthesis |
cIAI |
Ph II |
| Theravance Inc. (NASDAQ:THRX) |
TD-1792 |
Beta-lactam-glycopeptide hybrid |
Inhibit cell wall synthesis |
Gram-positive complicated skin and skin structure infections (cSSSI) |
Ph II |
| Wockhardt Ltd. (BSE:532300) |
WCK 771 |
Fluoroquinolone |
Inhibit DNA replication |
MRSA |
Ph II |
| Wockhardt Ltd. (BSE:532300) |
WCK 2349 |
Fluoroquinolone |
Inhibit DNA replication |
Gram-positive cSSSI |
Ph II |
| Nanotherapeutics Inc. |
Ramoplanin |
Lipoglycodepsipeptide |
Inhibit cell wall production |
CDAD |
Ph II |
| Anacor Pharmaceuticals Inc. (NASDAQ:ANAC) |
GSK2251052 (AN3365) |
Boron-containing leucyl-tRNA synthetase (LARS; LeuRS) inhibitor |
Inhibit LeuRS |
cUTI; cIAI |
Ph II suspended (B) |
| Cempra Inc. (NASDAQ:CEMP) |
Taksta sodium fusidate (CEM-102) |
Fusidane |
Inhibit protein synthesis |
Prosthetic joint infection |
Start Ph II (U.S.) in 4Q12 |
| 2M BioTech L.P. |
CBR-2092 |
Rifamycin-quinolone hybrid |
Inhibit DNA replication and RNA synthesis |
S. aureus infections |
Ph I |
| Achaogen Inc. |
ACHN-975 |
N-acetylglucosamine deacetylase (LpxC) inhibitor |
Inhibit LpxC |
Gram-negative infection |
Ph I |
| aRigen Pharmaceuticals Inc. |
ARH-1029 |
NA |
NA |
H. pylori infection |
Ph I (Japan/Korea) |
| aRigen Pharmaceuticals Inc./Green Cross Corp. |
WAP-8294A2 |
Depsipeptide |
Disrupt membrane |
MRSA |
Ph I (U.S.) |
| AstraZeneca plc (LSE:AZN) |
AZD5847 |
Oxazolidinone |
Inhibit protein synthesis |
TB |
Ph I |
| Basilea Pharmaceutica AG (SIX:BSLN) |
BAL30072 |
Beta-lactam (monocyclic) |
Inhibit cell wall synthesis |
Gram-negative infection |
Ph I |
| FAB Pharma S.A.S. |
FAB001 (MUT056399) |
FabI enoyl-(acyl carrier protein) reductase inhibitor |
Inhibit fabI |
S. aureus infection |
Ph I |
| GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) |
GSK2140944 |
NA |
Inhibit topoisomerase II (TOP2) |
Bacterial infection |
Ph I |
| Kalidex Pharmaceuticals Inc. |
KPI-10 |
Fluoroquinolone |
Inhibit DNA replication |
Gram-negative and Gram-positive infections |
Ph I |
| Kyorin Pharmaceutical Co. Ltd. (Tokyo:4569) |
KRP-AM1977X |
Quinolone |
Inhibit DNA replication |
Gram-positive infection |
Ph I (Japan) |
| MicuRx Pharmaceuticals Inc. |
MRX-I |
Oxazolidinone |
Inhibit protein synthesis |
Gram-positive infection |
Ph I |
| Novacta Biosystems Ltd. |
NVB302 |
Lantibiotic |
Inhibit cell wall synthesis |
C. difficile infection |
Ph I |
| Rempex Pharmaceuticals Inc. |
Carbavance (RPX7009 / biapenem) |
Beta-lactamase inhibitor with boron core (RPX7009); beta lactam (biapenem) |
Inhibit cell wall synthesis |
Gram-negative infection |
Ph I |
| Shionogi & Co. Ltd. (Tokyo:4507)/GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) |
S-649266 |
Beta-lactam |
Inhibit cell wall synthesis |
Bacterial infection |
Ph I (Japan) |
| Tetraphase Pharmaceuticals Inc. |
TP-2758 |
Tetracycline |
Inhibit protein synthesis |
cUTI |
Ph I |